Brooks Laboratories Ltd
NSE: BROOKS BSE: 533543
₹65.54
(6.54%)
Wed, 14 Oct 2026, 00:18 am
Market Cap (in Cr)206.5
PE Ratio14.61
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KBrooks Laboratories Cashflow
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deprecation and amortization | -3.11M | -3.96M | -4.45M | -5.19M | -6.11M | -6.56M | -8.14M | -8.32M | -11.04M | -11.60M | -16.72M | -64.45M | -65.00M | -66.48M | -71.43M | -73.51M | -70.27M | -17.73M | -16.02M |
| Accumulated depreciation, total | 0 | 0 | 0 | 0 | 0 | -29.01M | -37.14M | -45.24M | -56.53M | -66.84M | -16.72M | -80.97M | -145.24M | -191.96M | — | -323.77M | -69.90M | -83.48M | -95.14M |
| Cash from operating activities | 1.08M | 20.13M | 14.58M | 56.91M | 40.41M | -23.68M | 53.15M | 116.59M | 40.09M | 86.13M | 86.66M | -88.34M | -79.91M | -126.38M | 16.16M | -404.47M | -165.77M | -103.75M | 18.68M |
| Funds from operations | 17.17M | 42.66M | 36.47M | 59.90M | 93.48M | 94.92M | 79.58M | 77.23M | 79.93M | 64.62M | 31.14M | -109.23M | -92.16M | -50.21M | -57.50M | -161.21M | -280.04M | 26.96M | 43.90M |
| Net income (cash flow) | 11.25M | 35.80M | 29.61M | 51.96M | 68.88M | 88.36M | 71.44M | 72.39M | 94.67M | 106.33M | 16.67M | -138.13M | -148.05M | -243.76M | -193.75M | -112.90M | -208.92M | -195.92M | -99.67M |
| Depreciation & amortization (cash flow) | 3.11M | 3.96M | 4.45M | 5.19M | 6.11M | 6.56M | 8.14M | 8.32M | 11.04M | 11.60M | 16.72M | 64.45M | 65.00M | 66.48M | 71.43M | 73.51M | 70.27M | 17.73M | 16.02M |
| Depreciation/depletion | 3.02M | 3.88M | 4.37M | 5.10M | 6.03M | 6.56M | 8.14M | 8.32M | 11.04M | 11.60M | 16.72M | 64.45M | 64.80M | 66.16M | 70.02M | — | — | — | — |
| Amortization | 83.00K | 83.00K | 83.00K | 83.00K | 83.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200.00K | 321.00K | 1.41M | — | — | — | — |
| Deferred taxes (cash flow) | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-cash items | 3.00K | -122.00K | 1.00K | -1.00K | 14.40M | -3.34M | -24.39M | -6.80M | -6.76M | -53.88M | -10.41M | 1.66M | -7.68M | 18.45M | -39.00M | 4.26M | 33.39M | 204.89M | 125.80M |
| Changes in working capital | -16.09M | -22.52M | -21.89M | -2.98M | -53.06M | -118.60M | -26.43M | 39.36M | -39.84M | 21.51M | 55.52M | 20.90M | 12.25M | -76.17M | 73.66M | -243.26M | 114.27M | -130.72M | -25.22M |
| Cash from investing activities | -35.65M | -12.49M | -82.79M | -27.89M | -9.24M | -419.18M | -13.16M | -58.75M | -34.42M | -148.51M | -169.15M | -52.68M | 10.09M | -24.66M | -53.02M | 494.19M | 180.28M | 807.00K | -452.10M |
| Capital expenditures | -35.65M | -12.49M | -82.59M | -27.89M | -9.24M | -229.68M | -20.27M | -19.86M | -200.06M | -359.08M | -176.25M | -57.33M | -8.67M | -25.84M | -56.14M | -276.12M | -4.67M | -4.39M | -9.23M |
| Capital expenditures - fixed assets | -35.65M | -12.49M | -82.59M | -27.89M | -9.24M | -229.68M | -20.27M | -19.86M | -200.06M | -359.08M | -176.25M | -57.33M | -8.67M | -25.84M | -56.14M | -276.12M | -4.67M | -4.39M | -9.23M |
| Capital expenditures - other assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from financing activities | 36.11M | 43.07M | 37.95M | -42.43M | -31.04M | 620.98M | 2.30M | 3.32M | 3.74M | 51.13M | 80.19M | 148.95M | 88.36M | 130.02M | 41.74M | -72.51M | -40.32M | 103.97M | 432.60M |
| Free cash flow | -34.57M | 7.64M | -68.01M | 29.02M | 31.17M | -253.36M | 32.88M | 96.73M | -159.97M | -272.95M | -89.60M | -145.66M | -88.58M | -152.22M | -39.98M | -680.59M | -170.45M | -108.14M | 9.45M |
